Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

by · The Markets Daily

Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 95,505 shares, a decline of 99.1% from the August 15th total of 10,331,073 shares. Based on an average daily volume of 71,248 shares, the short-interest ratio is presently 1.3 days. Approximately 8.8% of the company’s stock are sold short.

Liminatus Pharma Trading Up 4.3%

Shares of LIMN traded up $0.15 during trading hours on Thursday, reaching $3.63. The stock had a trading volume of 19,007 shares, compared to its average volume of 619,206. The firm has a 50-day simple moving average of $5.35 and a 200 day simple moving average of $7.89. Liminatus Pharma has a 12 month low of $3.42 and a 12 month high of $141.50. The company has a market capitalization of $4.86 million, a price-to-earnings ratio of -0.15 and a beta of 5.30.

Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.50) EPS for the quarter.

Wall Street Analyst Weigh In

LIMN has been the topic of a number of research analyst reports. Weiss Ratings cut shares of Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Wall Street Zen lowered Liminatus Pharma to a “strong sell” rating in a research report on Saturday, August 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Check Out Our Latest Analysis on LIMN

Liminatus Pharma Company Profile

(Get Free Report)

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

See Also